{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:49:47Z","timestamp":1694998187822},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.diagmicrobio.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T16:25:01Z","timestamp":1470759901000},"page":"300-302","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013\u20132014)"],"prefix":"10.1016","volume":"86","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0005","first-page":"388","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"15","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0010","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0015","series-title":"M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0020","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/AAC.02330-13","article-title":"Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival","volume":"58","author":"Corey","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0025","first-page":"1970","article-title":"National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011","volume":"173","author":"Dantes","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0030","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0035","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0045","doi-asserted-by":"crossref","unstructured":"Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 Suppl 1:S81-7.","DOI":"10.1086\/653053"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0050","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12913-015-0917-x","article-title":"Healthcare utilization and costs associated with S aureus and P aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database","volume":"15","author":"Kyaw","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2016.08.005_bb0060","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality","volume":"61","author":"Lacy","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0065","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0070","doi-asserted-by":"crossref","unstructured":"Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5:S378-85.","DOI":"10.1086\/533594"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2016.08.005_bb0080","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/civ535","article-title":"The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"61","author":"Sandrock","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkt490","article-title":"Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure","volume":"69","author":"Torres","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.08.005_bb0095","author":"VIBATIV"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316302425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316302425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T10:24:10Z","timestamp":1536488650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316302425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0732889316302425"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.08.005","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013\u20132014)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}